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Fitness cost of chromosomal drug resistance-conferring
mutations
Abstract
To study the cost of chromosomal drug resistance mutations to bacteria, we investigated the fitness cost
of mutations that confer resistance to different classes of antibiotics affecting bacterial protein synthesis
(aminocyclitols, 2-deoxystreptamines, macrolides). We used a model system based on an in vitro
competition assay with defined Mycobacterium smegmatis laboratory mutants; selected mutations were
introduced by genetic techniques to address the possibility that compensatory mutations ameliorate the
resistance cost. We found that the chromosomal drug resistance mutations studied often had only a small
fitness cost; compensatory mutations were not involved in low-cost or no-cost resistance mutations.
When drug resistance mutations found in clinical isolates were considered, selection of those mutations
that have little or no fitness cost in the in vitro competition assay seems to occur. These results argue
against expectations that link decreased levels of antibiotic consumption with the decline in the level of
resistance.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 2002, p. 1204–1211 Vol. 46, No. 5
0066-4804/02/$04.000 DOI: 10.1128/AAC.46.5.1204–1211.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Fitness Cost of Chromosomal Drug Resistance-Conferring Mutations
Peter Sander,1,2* Burkhard Springer,2 Therdsak Prammananan,2† Antje Sturmfels,2 Martin Kappler,3
Michel Pletschette,2 and Erik C. Böttger1,2
Institut für Medizinische Mikrobiologie, Universität Zürich, CH-8028 Zürich, Switzerland,1 and Institut für Medizinische
Mikrobiologie2 and Institut für Biometrie,3 Medizinische Hochschule Hannover, 30625 Hannover, Germany
Received 21 August 2001/Returned for modification 27 November 2001/Accepted 24 January 2002
To study the cost of chromosomal drug resistance mutations to bacteria, we investigated the fitness cost of
mutations that confer resistance to different classes of antibiotics affecting bacterial protein synthesis (ami-
nocyclitols, 2-deoxystreptamines, macrolides). We used a model system based on an in vitro competition assay
with defined Mycobacterium smegmatis laboratory mutants; selected mutations were introduced by genetic
techniques to address the possibility that compensatory mutations ameliorate the resistance cost. We found
that the chromosomal drug resistance mutations studied often had only a small fitness cost; compensatory
mutations were not involved in low-cost or no-cost resistance mutations. When drug resistance mutations
found in clinical isolates were considered, selection of those mutations that have little or no fitness cost in the
in vitro competition assay seems to occur. These results argue against expectations that link decreased levels
of antibiotic consumption with the decline in the level of resistance.
The increasing rates of recovery of antimicrobial-resistant
microorganisms in hospital and community settings are of
growing concern (1, 42). Resistance may emerge from a mu-
tation in an intrinsic chromosomal gene or by acquisition of
exogenous genetic material bearing resistance determinants.
Resistance to antibiotics frequently reduces the fitness of bac-
teria in the absence of antibiotics; this is referred to as the
“cost” of resistance (38). In mathematical models, the fitness
cost of resistance is the primary parameter that determines
both the frequency of resistance at any given level of antibiotic
use and the rate at which that frequency will change with
changes in antibiotic use patterns (3, 20, 21).
Restricted use of antibiotics is advocated not only to contain
the dissemination of resistance but also to favor the nonexpan-
sion and, finally, the disappearance of the resistant bacteria
already present in human and environmental reservoirs (3, 38).
As a consequence of decreased use of antibiotics, rates of drug
resistance usually fall but do not vanish, and stable rates of
resistance in the apparent absence of direct selection pressure
has been observed (9, 12, 32). It is not clear whether this
persistence of resistant bacteria is due to (i) low-level antibiotic
contamination that maintains the selective pressure, (ii) selec-
tion by means other than antibiotics, or (iii) the stability of
resistance genes.
Analogous to the resistance mediated by exogenous genetic
elements (13, 14, 19), chromosomal drug resistance-conferring
mutations are commonly assumed to carry a fitness cost (38).
This is supported by the observation that some drug resistance
mutations selected in vitro involve a significant decrease in
bacterial fitness (4, 20, 36); this fitness burden can subse-
quently be ameliorated by compensatory mutations (4, 5, 36).
However, for streptomycin resistance-conferring rpsL muta-
tions, a high level of selection for no-cost drug resistance mu-
tations was suggested to exist in vivo (6). In order to investigate
whether this no-cost resistance mutation represents an isolated
observation or points to a more general biological phenome-
non, we examined the hypothesis that resistance mutations are
costly.
MATERIALS AND METHODS
Bacteria. Mycobacterium smegmatis rrnB represents a variant of M. smegmatis
mc2155 SMR5 with a single rRNA allele; M. smegmatis normally contains two
rRNA operons (33). Spontaneous drug-resistant mutants were selected on Luria-
Bertani agar plates containing clarithromycin (50 g/ml) or amikacin (20 g/ml).
M. smegmatis rrnB rpsL3 (strain 1682) is a streptomycin-sensitive derivative of
mc2155 with a single rRNA allele and was used to obtain streptomycin-resistant
mutants by selection on brain heart infusion (BHI) agar containing 20 g of
streptomycin per ml. In brief, sacB counterselection was used to inactivate the
rrnB operon, resulting in strain mc2155 rrnB (strain 1434) with a single rRNA
allele; subsequently, two additional rpsL genes were introduced into the chro-
mosome, resulting in mc2155 rrnB rpsL3 (39).
Drug-resistant mutants were purified by streaking them on selective agar and
were immediately frozen in 15% glycerol to prevent further genetic changes;
further passages were done in the absence of antibiotics.
Recombinant DNA techniques. Nucleic acids were analyzed by PCR-mediated
sequencing with rRNA-specific primers. Genomic DNA was isolated as de-
scribed previously; standard methods were used for restriction endonuclease
digestion of DNA and other manipulations. Single rRNA mutations were intro-
duced into integrative plasmid pMV361-H-rRNA (34), which carries the com-
plete rrnB operon of M. smegmatis, by PCR-mediated site-directed mutagenesis;
plasmid pMV361 integrates once into the bacterial genome, thus providing a
single copy of the mutated gene.
Transformation of mycobacteria. Strains M. smegmatis mc2155 rrnB and rrnB
rpsL3, which have single rRNA alleles, were used for the transformation ex-
periments. Transformants were selected primarily on BHI plates containing
hygromycin (50 g/ml); subsequently, RecA-mediated gene conversion was used
to obtain strains carrying homozygous mutant rRNA alleles (30); mutants were
passaged once on selective agar. The homogeneity of the mutations introduced
was verified by manual sequence analysis with 32P-labeled CTP and Sequenase
(U.S. Biochemicals); MICs were determined to verify the resistance phenotype.
Determination of bacterial fitness. The cost of a resistance mutation was
determined by direct competition against the drug-susceptible parental strain.
Equal densities of drug-susceptible and drug-resistant strains were mixed and
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incubated in antibiotic-free BHI medium; every 24 h, 0.05 ml of the grown
culture was transferred into 5 ml of fresh BHI medium for growth. Aliquots were
plated every 24 h onto drug-free BHI agar to count the number of colonies. The
number of drug-resistant bacterial cells was determined by plating the colonies
on BHI agar containing the respective drug (streptomycin, 10 g/ml; amikacin,
50 g/ml; clarithromycin, 50 g/ml); the number of parental drug-susceptible
cells was calculated as the total number of bacterial cells minus the number of
drug-resistant bacterial cells. The experiments were performed in triplicate with
three independent cultures. Serial dilutions of each aliquot were plated three
times, and a weighted mean according to the level of dilution was used for
analysis.
The difference in fitness between two competing strains at time t was computed
by use of the following function:
St ln  rt/Strt1/St1
1/8 (1)
where rt and st denote the absolute number of drug-resistant and drug-suscep-
tible cells at a given time t, respectively, and rt1 and st1 denote the number of
drug-resistant and drug-susceptible cells at the preceding time point, respec-
tively. St is called the selection coefficient at time t. The quotient of the ratios of
the cell numbers was standardized with the exponent 1/8 because cell numbers
were determined every eight generations.
The terms rt/rt1 and st/st1 give the growth rates for drug-resistant and
drug-susceptible strains, respectively (8). Hence, S can be interpreted as the
natural logarithm of the quotient of the growth rates of the competing strains. S
is equal to 0 if there is no difference in fitness between the competing strains, S
is negative if antibiotic resistance reduces bacterial fitness, and S is positive if
resistance increases bacterial fitness relative to that of the drug-susceptible com-
petitor strain.
Relative bacterial fitness at time t (fitt) was calculated as
fitt 1 St (2)
The cost per generation (cpg) was calculated as
cpg  1  eSt (3)
The cost per generation can be interpreted as 1 minus the quotient of the growth
rates. An analysis of variance was performed with St as the dependent variable
and the experiment as the random explanatory factor j (35):
Stj 0 j εtj (4)
where 0 is a nonrandom intercept, Stj denotes the selection coefficient at time
t and experiment j, and εtj is the normal distributed error term at time t and
experiment j. The overall St was estimated and tested against 0 on the basis of the
null hypothesis (H0) that 0 is equal to 0. The data for different time points from
one experiment were assumed to be independent. Given that the random factor
“experiment” had no significant influence, subsequent analyses were performed
without this factor and the data were assumed to be fully independent of each
other.
To eliminate dilution errors and to determine the cost of resistance more
precisely for no-cost and low-cost resistance mutations, additional experiments
were performed. Aliquots from the competition assay were taken at time zero (t0;
0 h) and time 6 (t6; 144 h, corresponding to 48 generations) and plated onto
nonselective agar; subsequently,100 individual colonies were picked at random
and the resistance phenotype was investigated for each colony individually to
determine the ratio of susceptible and resistant cells (at least three independent
experiments were performed for each mutant selected). This situation can be
reflected by the following cross tabulation:
t0 t6
r r0 r6 (5)
s s0 s6
where rt and st denote the absolute number of drug-resistant and drug-suscep-
tible cells at time t, respectively. St is a monotonic transformation of the odds
ratio (OR) of (5)
St ln r6/s6r0/s0
1/48  ln OR1/48	 (6)
Estimations of OR can be obtained by a logistic model (17):
ln
p
1 p 
0 
1 · t i (7)
where p is the probability that a drug-susceptible colony will be picked, t is the
time, i is a random parameter to allow variability between the experiments, and

0 and 
1 are the regression parameters. 
1 is an estimate for log OR, and a test
for H0 that 
1 is equal to 0 can be used to test if St is 0. To test whether the
bacterial fitness differed between bacteria with mutations introduced by site-
directed mutagenesis and spontaneous drug-resistant mutants, an interaction
term between time and the type of the mutation is added to the model (7):
ln
p
1 p 
0 
1 · t 
2 · t · type  i (8)
If the test for H0 that 
2 (another regression parameter) is equal to 0 is not
significant, the preceding model would be sufficient and no influence of the type
of mutation on St would be present. If the test is significant, an interaction term
would be necessary for the model; i.e., the type of mutation would have a
significant influence on St. All statistical calculations were performed with SAS
release 8.01.
Strains used for competition experiments. The following strain combinations
were used in the competition experiments: spontaneous streptomycin-resistant
mutants of mc2155 rrnB (strains 1644, 1646, and 1674) versus drug-susceptible
strain mc2155 rrnB (strain 1434); spontaneous streptomycin-resistant rrnB
rpsL3 mutants (strains 1592, 1630, 1632, 1634, 1636, and 1647) versus a drug-
susceptible rrnB rpsL3 strain (strain 1682); spontaneous amikacin-resistant
rrnB mutants (strains 1181, 1183, 1184, 1185, 1187, and 1194) versus drug-
susceptible rrnB strains (strains 1179, 1186, and 1193); and spontaneous clar-
ithromycin-resistant rrnB mutants (strains 1082, 1086, and 1089) versus a drug-
susceptible rrnB strain (strain 1179).
mc2155 rrnB rpsL3 transformed with pMV361-H-rRNA2058 (strain 1691)
was used as a drug-susceptible competitor strain (containing two wild-type 16S
rRNA alleles, one chromosomal and one plasmid derived) for the strains into
which the respective streptomycin resistance mutation was introduced by trans-
formation with mutagenized plasmid pMV361-H-rRNA2058 and subsequent
RecA-mediated gene conversion (two mutant 16S rRNA alleles, one chromo-
somal and one plasmid derived; strains 1683, 1684, 1687, 1688, 1689, 1699, and
1700).
An rrnB mutant transformed with pMV361-H-rRNA2058 (strain 1516) was
used as a susceptible competitor for the strains into which the 1408A3G resis-
tance mutation was introduced by transformation with mutagenized plasmid
pMV361-H-rRNA2058 and subsequent RecA-mediated gene conversion (strains
1512, 1513, 1514-A, and 1515-B).
An rrnB mutant transformed with pMV361-H-rRNA (strains 2014, 2015) was
the susceptible competitor for the strains into which the 2058A3G (strains 1998
and 1999) and 2059A3G (strains 2006 and 2007) resistance mutations were
introduced by transformation with mutagenized plasmid pMV361-H-rRNA.
For a summary of the strains used in this investigation, see Table 1.
Frequency of resistance mutations in clinical isolates. The literature was
searched for published molecular biology-based analyses of mycobacterial drug
resistance by use of the key words mycobacteria and drug resistance. Elimination
of reviews and descriptions of clonal outbreaks and multiple isolates resulted in
identification of 93 unique streptomycin-resistant strains of Mycobacterium tu-
berculosis for which the mechanism of resistance was characterized at the mo-
lecular level; 79 of these strains had one of the resistance mutations investigated
here and were included in the analysis; 14 strains had a resistance mutation not
investigated in this study (in RpsL at amino acid 88 and in rrn at positions 501,
912, and 913).
RESULTS
Ribosomal resistance due to point mutations in ribosomal
nucleic acids (rrn) has been recognized as a cause of clinically
acquired resistance to drugs that affect the translation appara-
tus in such important pathogens as M. tuberculosis, Helicobac-
ter pylori, and Mycoplasma pneumoniae (10, 11, 16, 22, 23, 24,
29, 31, 33, 40, 41).
A genetically well defined system was chosen to investigate
the cost of resistance of rrn mutations to avoid the influence of
an unknown or ill-defined genetic background, like those that
occur in clinical isolates. Derivatives of M. smegmatis with a
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single rRNA allele (33) were used to saturate the ribosomal
nucleic acids with drug resistance-conferring mutations by plat-
ing them on selective agar. A total of 40 independent in vitro
mutants were obtained. The resistance mutations were
mapped and found to locate in the rrn operon. With the ex-
ception of the 16S rRNA 524G3C mutation (which was de-
tected in 12 of 22 streptomycin-resistant mutants investigated),
all other mutations obtained are representative of those mu-
tations found in pathogens with clinically acquired drug resis-
tance (Table 2).
Fitness costs of spontaneous mutations. The changes in the
relative fitness of M. smegmatis strains carrying mutations that
confer ribosomal drug resistance were examined in a compe-
tition model in the absence of antibiotics. The model was
validated by using well-characterized mutations at amino acid
42 of the rpsL gene, which confers resistance to streptomycin;
TABLE 1. Strains used in this study
Strain Genotype Transformed plasmid Relevant phenotype Parental strain
Parental strains
0058 mc2155 Wild type STRr
0003 mc2155 SMR5 rpsL 42 Lvs3Arg 0058
1434 mc2155 rrnB rrnB::aph KANr 0058
1682 mc2155 rrnB rpsL3 rrnB::aph rpsL3 KANr GENr 1434
1179 rrnB rrnB::aph KANr 0003
1193 rrnB rrnA::aph KANr 0003
1186 rrnA rrnB::aph KANr 0003
Spontaneous resistant mutants
1644 RpsL 42 Lys3Asn STRr 1434
1646 RpsL 42 Lys3Thr STRr 1434
1674 RpsL 42 Lys3Arg STRr 1434
1592 rrs 526C3T STRr 1682
1630 rrs 526C3T STRr 1682
1632 rrs 523A3C STRr 1682
1634 rrs 522C3T STRr 1682
1636 rrs 522C3T STRr 1682
1647 rrs 524G3T STRr 1682
1181 rrs 1408A3G AMKr 1179
1183 rrs 1408A3G AMKr 1179
1184 rrs 1408A3G AMKr 1179
1185 rrs 1408A3G AMKr 1179
1187 rrs 1408A3G AMKr 1186
1194 rrs 1408A3G AMKr 1193
1082 rrl 2058A3G CLRr 1179
1086 rrl 2058A3G CLRr 1179
1089 rrl 2059A3G CLRr 1179
Genetically engineered strains
Streptomycin resistant
1691 pMV361-H-rRNA2058G HYGr, CLRr 1682
1683 pMV361-H-rRNA 524C 2058G HYGr, CLRr, STRr 1682
1684 pMV361-H-rRNA 524C 2058G HYGr, CLRr, STRr 1682
1687 pMV361-H-rRNA 526T 2058G HYGr, CLRr, STRr 1682
1688 pMV361-H-rRNA 526T 2058G HYGr, CLRr, STRr 1682
1689 pMV361-H-rRNA 526T 2058G HYGr, CLRr, STRr 1682
1699 pMV361-H-rRNA 523C 2058G HYGr, CLRr, STRr 1682
1700 pMV361-H-rRNA 523C 2058G HYGr, CLRr, STRr 1682
Aminoglycoside resistant
1516 pMV361-H-rRNA2058G HYGr HYGr, CLRr 1193
1512 pMV361-H-rRNA 1408G 2058G HYGr, CLRr, AMKr 1193
1513 pMV361-H-rRNA 1408G 2058G HYGr, CLRr, AMKr 1193
1514A pMV361-H-rRNA 1408G 2058G HYGr, CLRr, AMKr 1193
1515B pMV361-H-rRNA 1408G 2058G HYGr, CLRr, AMKr 1193
Clarithromycin resistant
2014 pMV361-H-rRNA HYGr 1193
2015 pMV361-H-rRNA HYGr 1193
1998 pMV361-H-rRNA2058G HYGr CLRr 1193
1999 pMV361-H-rRNA2058G HYGr CLRr 1193
2006 pMV361-H-rRNA 2059G HYGr CLRr 1193
2007 pMV361-H-rRNA 2059G HYGr CLRr 1193
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the mutations chosen have been characterized previously and
are known to affect bacterial fitness and virulence to different
degrees: the nonrestrictive Lys3Arg mutation is a no-cost
resistance mutation which does not affect fitness, and the re-
strictive Lys3Asn and Lys3Thr mutations have significant
effects on fitness (4, 5, 36). The growth of the mutant with the
nonrestrictive mutation was similar to that of the wild type,
while the wild type outgrew the restrictive mutants (Fig. 1; the
costs of resistance were calculated as 14.1 and 14.9% per gen-
eration, respectively). The costs of these resistance determi-
nants are in close agreement with those observed in previous
experiments for resistant Escherichia coli and Salmonella en-
terica serovar Typhimurium strains (5, 36).
As shown in Fig. 1, three rrn mutations causing resistance to
streptomycin, i.e., 523A3C, 526C3T, and 522C3T, had costs
of resistance of 5.9, 8.5, and 8.9% per generation, respectively.
The strain with the 16S rRNA mutation 524G3C, which is the
streptomycin resistance mutation most frequently generated in
vitro but which is not found in clinical drug-resistant isolates,
had a greater than 30% growth disadvantage per generation
relative to that of the streptomycin-sensitive parental strain in
this assay (39).
In contrast to their effect on resistance to streptomycin,
alterations of ribosomal proteins do not play a major role in
acquired chromosomal resistance to 2-deoxystreptamines and
macrolides, but resistance is predominantly due to mutations
in rrn (24, 29, 33). None of the resistance-conferring mutations
(16S rRNA 1408A3G, 23S rRNA2058A3G, 23S rRNA
2059A3G) was found to affect bacterial fitness to a major
degree (Table 3).
The fitness cost was determined more precisely for resis-
tance mutations with low or no costs (1408G, 2058G, and
2059G; see Materials and Methods for details). Mutations
1408G and 2059G demonstrated small but significant fitness
costs (2 to 3% per generation). Mutation 2058G had a non-
significant cost of 0.5 to 1.4% per generation, well within the
range of the no-cost RpsL 42 Arg mutation (Table 4).
Low fitness costs are not due to compensatory mutations.
The frequency with which mutants appeared on the selection
plate corresponded to the frequency of appearance of single
point mutations in M. smegmatis rRNA (108 to 109) (33).
The frequency of a double mutation is so low that it would be
unlikely that any of the mutants studied would have another,
compensatory mutation. This tentative conclusion was ver-
ified experimentally. Selected mutations were introduced
by recombinant DNA techniques to ensure that the strains
used for competition were isogenic; these mutations were
16S rRNA 523A3C, 524G3C, 526C3T, 1408A3G, 23S
rRNA2058A3G, and 2059A3G. The strains into which all of
the mutations were introduced by site-directed mutagenesis
showed fitness characteristics similar to those of the spontane-
ous drug-resistant mutants (Fig. 1; Tables 3 and 4); a signifi-
cant difference between genetic and spontaneous mutants
could not be found for any of the mutations (523C, P  0.73;
524C, P  0.66; 526T, P  0.65; 1408G, P  0.73; 2058G, P 
0.06; 2059G, P  0.84). These experiments appear to disprove
TABLE 2. Resistance mutations investigated and corresponding resistance phenotype
Type of rRNA
mutation
No. of spontaneous mutants obtained
by selective plating/total no.
of isolates testedb
Resistance phenotype MIC
c
(g/ml)
Resistance mutation
observed in clinical
pathogensd
16S rRNA 522 C3T 2/22 Streptomycin 250 
16S rRNA 523 A3Ca 1/22 Streptomycin 125 
16S rRNA 524 G3Ca 12/22 Streptomycin 500 
16S rRNA 526 C3Ta 7/22 Streptomycin 125 
16S rRNA 1408 A3Ga 10/10 2-Deoxystreptamines 500e 
23S rRNA2058 A3Ga 7/8 Macrolides, lincosamides, streptogramin B 128f 
23S rRNA 2059 A3Ga 1/8 Macrolides, streptogramin B 128f 
a The indicated mutations were also introduced into M. smegmatis by recombinant DNA techniques.
b A total of 40 independent laboratory mutants were obtained in vitro, 22 were resistant to streptomycin, 10 were resistant to 2-deoxystreptamines, and 8 were
resistant to macrolides.
c The MICs of drug-susceptible M. smegmatis strains are as follows: streptomycin, 1.0 g/ml; amikacin, 0.6 g/ml; clarithromycin, 0.06 g/ml.
d Tabulated from previous reports (10, 11, 16, 22, 23, 24, 29, 31, 33, 40, 41).
e Amikacin was chosen as a representative of the 2-deoxystreptamines.
f Clarithromycin was chosen as a representative of the macrolides.
TABLE 3. St and cost of resistance of mutations investigated
a
Mutation St(1 SE [102])b
P
value
Cost per
generation
(%)
Relative fitness
(95% confidence
interval)
Streptomycin
RpsL 42 Arg 1.0  1.5 0.48 0.99 95.8–102.1
RpsL 42 Asn 15.2  1.9 0.01 14.10 79.9–89.6
RpsL 42 Thr 16.2  3.3 0.01 14.98 76.4–91.1
rrn 522 Tc 9.3  1.3 0.01 8.88 88.0–93.3
rrn 523 Cc 6.1  1.5 0.01 5.92 90.7–97.0
rrn 523 Cd 5.4  1.4 0.01 5.26 91.4–97.7
rrn 524 Cc 39.3  5.1 0.01 32.50 44.5–77.0
rrn 524 Cd 41.6  2.9 0.01 34.03 51.4–65.4
rrn 526 Tc 8.9  1.8 0.01 8.52 77.1–95.0
rrn 526 Td 7.9  0.9 0.01 7.60 90.2–94.0
2-Deoxystreptamines
rrn 1408Gc 1.7  2.5 0.52 1.69 92.6–104.1
rrn 1408Gd 3.0  2.2 0.13 2.96 92.4–101.7
Macrolides
rrn 2058Gc 2.0  2.1 0.36 1.98 93.4–102.6
rrn 2059Gc 2.0  3.4 0.57 1.98 90.5–105.6
a Determined by analysis of variance (F test).
b Estimated by direct competition against an equal density of the drug-suscep-
tible parental strain.
c Spontaneous mutants.
d Recombinant mutants.
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the hypothesis that compensatory mutations which could have
compensated for an initial cost of resistance had taken place
during the procedure used for the isolation of the spontaneous
drug-resistant mutants (4, 5, 7, 18, 36).
In vivo frequency of resistance mutations. The multiplicity
of different chromosomal mutations that conferred resistance
to streptomycin (rpsL and rrn) allowed us to test if the fre-
quency of a resistance mutation in clinical drug-resistant iso-
lates is a function of the relative fitness of the mutation, as
determined with the model system presented here. To address
this issue, previously described mutations that confer resis-
tance to streptomycin in clinical isolates of M. tuberculosis were
determined from the literature. M. tuberculosis, like most other
species of clinically relevant mycobacteria, carries a single
rRNA operon in its genome, which allows a comparison with
results obtained in our model system using single rRNA allelic
strains of M. smegmatis. Figure 2 demonstrates that a strong
correlation between the frequency of clinical isolates with a
given resistance mutation and the relative fitness of the corre-
sponding mutation exists. Assuming that the fitness of resistant
strains is less than or equal to the fitness of the drug-suscep-
tible parental strain, the correspondence function should be
asymptotic to y equal to 100% and can be described by y  1 
a  ebxc. The model was fit to the measured data by using an
implementation of the nonlinear least-squares Marquardt-Lev-
enberg algorithm; and the values of the parameters were esti-
mated to be as follows: a  0.18, b  3.13, and c  0.46.
To test if the higher frequency of particular mutations in
vivo is due to the more frequent generation of those mutations,
i.e., a higher mutation rate, we plotted the frequency of resis-
tance mutations generated in vitro in the laboratory versus
cost. In contrast to clinically acquired resistance mutations, no
correspondence between the frequency of a resistance muta-
tion and the fitness cost was observed (Fig. 2).
DISCUSSION
Competition experiments of the type used here are able to
detect statistically significant fitness differences larger than 2%
per generation (4, 5, 36). Although smaller fitness differences
might have some effects, our data suggest the following con-
clusions: (i) chromosomal resistance mutations found in labo-
ratory (in vitro)-derived spontaneous mutants may be cost neu-
FIG. 1. Determination of bacterial fitness by competitive growth.
(A) rpsL mutants; (B) streptomycin resistance-conferring 16S rRNA
mutations (spontaneous mutants); (C) streptomycin resistance-confer-
ring 16S rRNA mutations (mutations introduced by site-directed mu-
tagenesis). The mean of at least two independent experimental deter-
minations is given. (A) RpsL 42 Lys3Arg (F; strain 1674); RpsL 42
Lys3Asn (; strain 1644); RpsL 42 Lys3Thr (Œ; strain 1646). (B) 16S
rRNA 522C3T (} strains 1634 and 1636); 16S rRNA 523A3C (F;
strain 1632); 16S rRNA 524G3C (Œ; 1647); 16S rRNA 526C3T (;
strains 1592 and 1630). (C) 16S rRNA 523A3C (F; strains 1699 and
1700); 16S rRNA 524G3C (Œ; strains 1684 and 1683); 16S rRNA
526C3T (; strains 1687, 1688, and 1689). Cultures were inoculated
with equal numbers of the drug-resistant mutant and the drug-suscep-
tible parental strain, and the ratio of the number of resistant organ-
isms/number of susceptible organisms recovered was determined after
the indicated number of generations; M. smegmatis has a doubling time
of 3 h.
TABLE 4. St and relative fitness of mutations investigated
Mutation No.d St(1 SE [102])a
P
value
Cost per
generation
(%)
Relative fitness
(95% confidence
interval)
RpsL 42 Arg 9 0.98  0.37 0.98 98.23–99.74
rrn 1408Gb 18 3.10  0.74 0.01 3.05 95.45–98.35
rrn 1408Gc 13 2.88  0.59 0.01 2.84 95.96–98.28
rrn 2058Gb 6 0.46  0.29 0.12 0.46 98.96–100.12
rrn 2058Gc 3 1.40  0.40 0.01 1.39 97.81–99.39
rrn 2059Gb 9 2.63  0.83 0.01 2.60 95.74–99.00
rrn 2059Gc 6 2.47  0.23 0.01 2.44 97.08–98.99
a Estimated by direct competition against an equal density of the drug-suscep-
tible parental strain.
b Spontaneous mutants.
c Recombinant mutants.
d Number of independent experiments.
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tral; (ii) the failure to detect the costs of resistance in these
spontaneous mutants, and probably also in mutants detected in
nature (clinical isolates), is not due to compensatory muta-
tions; and (iii) under natural conditions (clinical isolates),
strong selection pressure seems to exist for those drug resis-
tance mutations which impose little if any burden on fitness,
i.e., mutations which do not confer a substantial cost in the
absence of antibiotics.
As a starting point, we searched the literature for different
resistance mutations occurring in a variety of pathogens; the
experimental investigations, however, were conducted with M.
smegmatis, which was used as a model system. We suggest that
the findings observed in our model system allow us to draw
more general conclusions, as comparable costs of resistance
were determined for mutations investigated previously in other
microorganisms, i.e., rpsL mutations 42 Lys3Arg, Lys3Asn,
Lys3Thr, which exhibited fitness costs of 0, 14, and 15%,
respectively, in E. coli, S. enterica serovar Typhimurium, and
M. smegmatis (5, 36) (Table 3).
Different constraints have been postulated to affect the
translation machinery under various in vitro and in vivo con-
ditions (2, 25). The selection of mutant genotypes observed in
vivo and determined in the in vitro competition model to be
no-cost mutations suggests that the measurements obtained in
vitro adequately reflect the measurements obtained in the in
vivo situation. While determination of a mutation as no cost
(within the limitations that accompany the use of a model
organism) conflicts with the assumption that resistance muta-
tions are costly, one cannot exclude a hypothetical condition in
which some sort of difference in fitness would become mani-
fest. However, the selection of no-cost resistance mutations
observed in clinical isolates exposed to complex and fluctuating
conditions as well as heterogeneous habitats makes this possi-
bility unlikely.
In contrast to competitive environments such as clinical in
vivo conditions, the use of a compartmentalized experimental
environment, i.e., solid medium, for selection of drug-resistant
mutants provides data on the frequency and type of resistant
variants largely irrespective of a fitness cost (variants with all
possible alleles capable of surviving the selection procedure
will grow). The observation that clinically acquired resistance
rarely involves mutations with a cost can be ascribed to two
different mechanisms: (i) a priori, mutations that confer a
substantial cost (e.g., mutations for resistance to aminoglyco-
sides of the 2-deoxystreptamine type) do not arise even under
in vitro conditions in the laboratory, as the functional con-
straints of the target molecule seem to allow only mutations
that are both cost neutral and able to produce a resistance
phenotype; and (ii) mutations that confer a cost occur under in
vitro conditions in the laboratory (e.g., mutations for resistance
to streptomycin), but there is selection in vivo for low-cost
resistance mutations. This selection might be explained by fluc-
tuating environments, i.e., expansion of mutants experiencing a
low cost of resistance in the absence of antibiotics during
periods in which selection for antibiotic resistance is removed.
While our findings do not deny the existence of compensa-
tory mutations (4, 5, 36), they indicate that under natural in
vivo conditions these may be of minor relevance to the epide-
miology of drug resistance. The likelihood that a costly resis-
tance mutation is ameliorated by an additional compensatory
mutation is far greater than the likelihood that a no-cost re-
sistance mutation (occurring roughly at the same frequency as
a costly resistance mutation) is ameliorated, making the sce-
nario of costly but compensated resistance mutations unlikely
in nature. In principle, resistance mutations that are acquired
in vivo and that carry a cost might therefore be found only
when a cost-neutral resistance mutation does not exist for a
given drug (5, 27). The eventual observation that a costly
FIG. 2. Relationship between frequency of streptomycin resistance
mutations and relative fitness. (A) Clinical M. tuberculosis isolates: },
RpsL 42 Lys3Thr; , RpsL 42 Lys3Arg; F, 16S rRNA 522C3T; ,
16S rRNA 523A3C; Œ, 16S rRNA 526C3T; data were tabulated
from previous reports (10, 11, 15, 23, 26, 28, 40). (B) In vitro rpsL
mutants of M. smegmatis mc2155: , 42 Lys3Arg; }, 42 Lys3Thr; F,
42 Lys3Asn; data were tabulated from reference 6. (C) In vitro 16S
rRNA mutants of M. smegmatis rrnB rpsL3: }, 524G3C; Œ,
526C3T; F, 522C3T; , 523A3C.
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resistance mutation will emerge in a single patient (e.g., strep-
tomycin resistance mutation RpsL 42 Lys3Thr, which was
found in 1 of 79 streptomycin-resistant M. tuberculosis isolates)
probably reflects the stochastic probability of a resistance mu-
tation in a bacterial population of limited size. It is under these
circumstances that compensatory mutations that ameliorate
the cost of resistance are likely to develop (27, 37).
Two outcomes of resistance mutations are feasible: fixation
or elimination (Table 5). For a costly resistance mutation, e.g.,
the streptomycin resistance mutation 523A3C, which carries a
cost of resistance of 5% per generation, 359 generations would
be required for the mutation to become fixed, i.e., for isolates
of the compensated resistance genotype to become the domi-
nant (99%) drug-resistant population, assuming that the fre-
quency of a compensatory mutation is 106 (5). These calcu-
lations are in line with the finding that the compensated
resistance genotype is less frequent in vivo than in vitro (27).
On the other hand, it will be difficult to eliminate resistance
mutations with a low fitness cost even in the absence of com-
pensatory mutations. By assuming a population of 99% resis-
tant cells and a cost per generation of 2%, more than 1,000
generations are required to lower the existing frequency of
resistance to the frequency of resistance resulting from spon-
taneous mutations (frequency of spontaneous drug-resistant
mutants, 108). For M. tuberculosis, which has an estimated
generation time of 24 h, this would correspond to more than 3
years of total absence of the corresponding drug.
Our investigations focused on the fitness cost of chromo-
somal drug resistance. The epidemiology of drug-resistant
pathogens is more complex and involves transmission and
clearance of microbes from infected hosts. Although we hesi-
tate to generalize our findings, the observation of no-cost or
low-cost mutation types in clinical situations for resistance to
different classes of antibiotics that act on the ribosome suggests
that these observations may reflect a general biological phe-
nomenon. Our results indicate the limitations of strategies for
the containment of resistance based solely on restrictive drug
use because, due to a missing fitness burden, negative selection
pressure for such mutations does not seem to exist in an anti-
biotic-free environment. These results are consistent with the
hypothesis that even if the rate of antibiotic consumption is
reduced, in places where resistance is already common, the
frequency of resistance will not decline rapidly, if at all (1, 20).
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